Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations

Am J Cardiol. 2003 May 1;91(9):1110-3. doi: 10.1016/s0002-9149(03)00159-0.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angina, Unstable / drug therapy
  • Anticoagulants / blood*
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use
  • Blood Coagulation
  • Blood Coagulation Tests*
  • Endopeptidases*
  • Female
  • Fibrinolytic Agents*
  • Hirudins / analogs & derivatives*
  • Hirudins / blood*
  • Hirudins / pharmacology
  • Humans
  • Male
  • Peptide Fragments / blood*
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use
  • Point-of-Care Systems*
  • Prothrombin / antagonists & inhibitors
  • Recombinant Proteins / blood*
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Whole Blood Coagulation Time

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Prothrombin
  • Factor IIa
  • Endopeptidases
  • ecarin
  • bivalirudin